International journal of radiation oncology, biology, physics 2009-07-01
Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas.
Abstract
Purpose
Radiotherapy (XRT) for spine sarcomas is constrained by spinal cord, nerve, and viscera tolerance. Negative surgical margins are uncommon; hence, doses of >or=66 Gy are recommended. A Phase II clinical trial evaluated high-dose photon/proton XRT for spine sarcomas.
Methods and materials
Eligible patients had nonmetastatic, thoracic, lumbar, and/or sacral spine/paraspinal sarcomas. Treatment included pre- and/or postoperative photon/proton XRT with or without radical resection; patients with osteosarcoma and Ewing's sarcoma received chemotherapy. Shrinking fields delivered 50.4 cobalt Gray equivalent (Gy RBE) to subclinical disease, 70.2 Gy RBE to microscopic disease in the tumor bed, and 77.4 Gy RBE to gross disease at 1.8 Gy RBE qd. Doses were reduced for radiosensitive histologies, concurrent chemoradiation, or when diabetes or autoimmune disease present. Spinal cord dose was limited to 63/54 Gy RBE to surface/center. Intraoperative boost doses of 7.5 to 10 Gy could be given by dural plaque.
Results
A total of 50 patients (29 chordoma, 14 chondrosarcoma, 7 other) underwent gross total (n = 25) or subtotal (n = 12) resection or biopsy (n = 13). With 48 month median follow-up, 5-year actuarial local control, recurrence-free survival, and overall survival are: 78%, 63%, and 87% respectively. Two of 36 (5.6%) patients treated for primary versus 7/14 (50%) for recurrent tumor developed local recurrence (p < 0.001). Five patients developed late radiation-associated complications; no myelopathy developed but three sacral neuropathies appeared after 77.12 to 77.4 Gy RBE.
Conclusions
Local control with this treatment is high in patients radiated at the time of primary presentation. Spinal cord dose constraints appear to be safe. Sacral nerves receiving 77.12-77.4 Gy RBE are at risk for late toxicity.
Related Questions
In a patient with an R1 resection of a chordoma who has declined proton therapy, what alternative radiation modality would you recommend?
Chordomas are aggressive and locally invasive tumors that commonly arise in the sacrum, skull base, or rarely the mobile spine. Resection is considered the first-line treatment; however, wide margins are difficult to achieve without significant morbidity. By nature of their site of origin near or ad...
What do you consider a curative radiation dose for a sarcoma?
This is a difficult predicament. We would certainly try to re-resect if at all possible; if not, a consideration could always be made for an amputation, but we try to avoid this if at all possible. Other options during the time of resection are consideration for brachytherapy. We would also discuss ...
What is an appropriate target volume for a chordoma or chondrosarcoma after a gross total resection?
The CTV for postop chordoma or chondrosarcoma after gross total resection should include the entire surgical resection cavity as well as incision and drain sites with a 1 cm margin for the initial 50.4 Gy. Then cone down off the incision and drain site and cover the high risk margins based on the or...
What are reasonable SBRT dose constraints for the lumbosacral plexus?
There are published dose tolerance guidelines for the sacral plexus with the AAPM TG101 report Benedict et al. Med. Phys 37(8): 4078-4101, 2010. Realize these have not been validatedOn page 4086, there is a table with suggested dose constraints for a 3 fraction regimen that include a threshold dose ...